

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

**LOBBYING REPORT****Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page**

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP	
<b>2. Address</b> Address1 <u>1800 CONCORD PIKE, P.O. BOX 15437</u> Address2 _____ City <u>WILMINGTON</u> State <u>DE</u> Zip Code <u>19850-5437</u> Country <u>USA</u>	
<b>3. Principal place of business (if different than line 2)</b> City _____ State _____ Zip Code _____ Country _____	
<b>4a. Contact Name</b> Ms. <u>Kate Belinski</u>	<b>b. Telephone Number</b> <u>2026615599</u>
<b>c. E-mail</b> <u>belinskik@ballardspahr.com</u>	
<b>5. Senate ID#</b> <u>54073-12</u>	
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP	<b>6. House ID#</b> <u>349750000</u>

**TYPE OF REPORT**8. Year 2021 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31) 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity **INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13**

<p align="center"><b>12. Lobbying</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p><b>EXPENSE</b> relating to lobbying activities for this reporting period were:</p> <p><u>Less than \$5,000</u> <input type="checkbox"/></p> <p><u>\$5,000 or more</u> <input checked="" type="checkbox"/> \$ <u>1,370,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	---

Signature Digitally Signed By: Kate BelinskiDate 1/21/2022  
12:12:05 PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
- H.R. 19 / S. 2164, the Lower Costs, More Cures Act.
- H.R. 3749, To amend title XXVII of the Public Health Services Act to expand the availability of coverage for lung cancer screenings without the imposition of cost sharing.
- Issues related to Cures 2.0.
- Issues related to drug pricing.
- COVID-19 vaccine and therapy development.
- Issues related to health equity and clinical trials
- H.R. 5376 Build Back Better Act
- Issues related to drug regulation & approval pathways
- S.2911, Seniors Prescription Drug Relief Act
- Issues related to value-based arrangements
- Oncology Care Model / Oncology Care First
- H.R. 1730/S. 670- Speeding Therapy Access Today Act;
- H.R. 483/S. 350 - Newborn Screening Saves Lives Act
- Diverse and Equitable Participation in Clinical Trials Act Discussion Draft
- General issues related to orphan disease drugs;
- FDA modernization policy issues;
- Reauthorization of newborn screening programs;
- Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients;
- General issues related to diagnostics for patients with rare diseases
- Cancer screening, diagnostics and treatment
- H.R 5260 Reduced Costs and Continued Cares Act
- Cancer screening, diagnostics and treatment
- Prescription drug electronic labeling

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), White House Office, Office of Science & Technology Policy (OSTP)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

- Issues related to Medicare Parts B and D pricing reform, H.R. 3684, S. 2327, Senate
- S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act.
- Issues related to CMS rulemaking [CMS-4190-F3, CMS-2482-P2].
- S. 2614, the NOVEL Act
- Medicare Multi-Cancer Early Detection Screening Coverage; H.R. 1946, S. 1873
- H.R. 5030, S. 2706 DIVERSE Trails Act
- H.R. 3085, S. 1548 ENACT Act of 2021
- H.R. 5260 - Reduced Costs and Continued Cures Act; Build Back Better Act
- General issues related to patient access to rare disease therapies, Part B and Part D drugs;
- Issues related to home infusion for Part B patients;
- Value-based payment arrangements;
- Efforts to improve coding, coverage, and access for rare disease therapies;
- Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies;
- General issues related to telemedicine
- Issues related to 340B

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- Issues related to the 340B drug discount program.
- Discussions related to an appropriations hold on funding for a 2014 FDA rule that would move package inserts (PI) from paper to digital form–e-labeling.
- FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376)

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

- Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
- S. 1435, the Affordable Prescriptions for Patients Act.
- H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act.
- H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act.
- H.R. 2883 Stop Stalling Access to Affordable Medications
- H.R. 2891 Preserve Access to Affordable Generics and Biosimilars Act
- Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform
- S. 2428, the False Claims Amendments

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Susie	Ahn			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

<ul style="list-style-type: none"> <li>• Issues related to international and corporate tax reform.</li> <li>• H.R. 5376 Build Back Better Act</li> <li>• Issues related to the Orphan Drug Tax Credit</li> </ul>
--

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
--

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Susie	Ahn			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

--

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

• H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act  
 • H.R. 6119 Further Extending Government Funding Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform  
• S. 1435, the Affordable Prescriptions for Patients Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Susie	Ahn			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

\_\_\_\_\_

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
<b>1</b>	_____	_____	<b>3</b>	_____	_____
<b>2</b>	_____	_____	<b>4</b>	_____	_____

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

--	--	--	--	--	--	--	--	--

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address	State/Province	Zip	Country	City	Country
	City				State	

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1	2	3
---	---	---

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			
	City			City		%
				State		
				Country		

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1	3	5
2	4	6

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)